AN2 Therapeutics Key Executives
This section highlights AN2 Therapeutics's key executives, including their titles and compensation details.
Find Contacts at AN2 Therapeutics
(Showing 0 of )
AN2 Therapeutics Earnings
This section highlights AN2 Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for AN2 Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $77.00K | $- | $- | $- |
| Gross Profit | $- | $-77.00K | $- | $- | $- |
| Gross Profit Ratio | 0.00% | - | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $54.87M | $29.51M | $16.91M | $6.02M | $4.89M |
| General and Administrative Expenses | $14.76M | $12.75M | $4.67M | $1.26M | $1.73M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $287.27K |
| Selling General and Administrative Expenses | $14.76M | $12.75M | $4.67M | $1.26M | $289.00K |
| Other Expenses | $- | $-45.00K | $-38.00K | $-6.32M | $- |
| Operating Expenses | $69.64M | $42.26M | $21.57M | $7.28M | $5.18M |
| Cost and Expenses | $69.64M | $42.26M | $21.57M | $7.28M | $5.18M |
| Interest Income | $- | $1.35M | $69.00K | $3.00K | $- |
| Interest Expense | $- | $514.00K | $- | $- | $- |
| Depreciation and Amortization | $69.64M | $77.00K | $21.57M | $7.28M | $31.07M |
| EBITDA | $4.90M | $-42.26M | $- | $-6.32M | $- |
| EBITDA Ratio | - | - | 0.00% | - | 0.00% |
| Operating Income | $-69.64M | $-42.26M | $-21.57M | $-7.28M | $-5.18M |
| Operating Income Ratio | - | - | - | - | - |
| Total Other Income Expenses Net | $4.90M | $1.31M | $31.00K | $-6.32M | $-457.00K |
| Income Before Tax | $-64.73M | $-40.96M | $-21.54M | $-13.60M | $-5.63M |
| Income Before Tax Ratio | - | - | - | - | - |
| Income Tax Expense | $- | $514.00K | $-69.00K | $-3.00K | $-31.07K |
| Net Income | $-64.73M | $-41.47M | $-21.47M | $-13.60M | $-5.63M |
| Net Income Ratio | - | - | - | - | - |
| EPS | $-2.74 | $-2.14 | $-1.15 | $-0.73 | $-0.30 |
| EPS Diluted | $-2.74 | $-2.14 | $-1.15 | $-0.73 | $-0.30 |
| Weighted Average Shares Outstanding | 23.60M | 19.40M | 18.74M | 18.74M | 18.74M |
| Weighted Average Shares Outstanding Diluted | 23.60M | 19.40M | 18.74M | 18.74M | 18.74M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $80.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $- | $- | $40.00K | $- | $21.00K | $19.00K | $20.00K | $20.00K | $19.00K | $- | $- | $- | $- | $- |
| Gross Profit | $- | $- | $- | $- | $40.00K | $- | $-21.00K | $-19.00K | $-20.00K | $-20.00K | $-19.00K | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 50.00% | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $5.40M | $8.29M | $12.15M | $14.65M | $14.92M | $14.43M | $13.54M | $11.98M | $8.75M | $8.43M | $6.70M | $5.63M | $5.81M | $5.34M | $4.10M | $1.65M |
| General and Administrative Expenses | $3.21M | $3.48M | $3.73M | $3.64M | $3.90M | $3.75M | $3.06M | $4.05M | $3.72M | $3.34M | $3.63M | $2.05M | $1.78M | $1.59M | $898.00K | $401.00K |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $3.21M | $3.48M | $3.73M | $3.64M | $3.90M | $3.75M | $3.06M | $4.05M | $3.72M | $3.34M | $3.63M | $2.05M | $1.78M | $1.59M | $898.00K | $401.00K |
| Other Expenses | $-9.00K | $2.24M | $- | $1.68M | $1.92M | $1.47M | $797.00K | $716.00K | $4.00K | $-35.00K | $-15.00K | $1.00K | $22.00K | $-36.00K | $-24.00K | $- |
| Operating Expenses | $8.60M | $14.01M | $15.88M | $18.30M | $18.82M | $18.18M | $16.60M | $16.04M | $12.48M | $11.77M | $10.33M | $7.68M | $7.59M | $6.93M | $5.00M | $2.05M |
| Cost and Expenses | $8.60M | $14.01M | $15.88M | $18.30M | $18.82M | $18.18M | $16.60M | $16.04M | $12.48M | $11.77M | $10.33M | $7.68M | $7.59M | $6.93M | $5.00M | $2.05M |
| Interest Income | $- | $- | $- | $- | $- | $- | $- | $- | $630.00K | $466.00K | $228.00K | $27.00K | $27.00K | $25.00K | $15.00K | $2.00K |
| Interest Expense | $- | $- | $- | $- | $716.00K | $- | $- | $- | $945.00K | $- | $228.00K | $27.00K | $- | $25.00K | $15.00K | $2.00K |
| Depreciation and Amortization | $- | $2.24M | $- | $18.30M | $18.82M | $18.18M | $21.00K | $19.00K | $20.00K | $20.00K | $19.00K | $7.68M | $7.59M | $6.93M | $5.00M | $2.05M |
| EBITDA | $-8.61M | $-11.77M | $-15.88M | $- | $-16.20M | $-18.18M | $-16.60M | $-16.04M | $-13.02M | $-11.77M | $-10.33M | $-7.68M | $- | $- | $- | $- |
| EBITDA Ratio | - | - | - | 0.00% | -20251.25% | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-8.60M | $-14.01M | $-15.88M | $-18.30M | $-18.82M | $-18.18M | $-16.60M | $-16.04M | $-12.48M | $-11.77M | $-10.33M | $-7.63M | $-7.59M | $-6.93M | $-5.00M | $-2.05M |
| Operating Income Ratio | - | - | - | - | -23518.75% | - | - | - | - | - | - | - | - | - | - | - |
| Total Other Income Expenses Net | $1.08M | $1.27M | $1.45M | $1.68M | $1.92M | $1.47M | $797.00K | $716.00K | $634.00K | $431.00K | $213.00K | $28.00K | $49.00K | $-11.00K | $-9.00K | $2.00K |
| Income Before Tax | $-7.52M | $-12.75M | $-14.44M | $-16.62M | $-16.90M | $-16.71M | $-15.80M | $-15.32M | $-11.84M | $-11.34M | $-10.12M | $-7.66M | $-7.54M | $-6.94M | $-5.01M | $-2.05M |
| Income Before Tax Ratio | - | - | - | - | -21122.50% | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax Expense | $- | $- | $- | $-18.30M | $-18.82K | $-18.18K | $-21.00K | $-716.00K | $945.00K | $-431.00K | $-441.00K | $-55.00K | $-7.62M | $-6.96M | $-5.01M | $-2.05M |
| Net Income | $-7.52M | $-12.75M | $-14.44M | $-16.62M | $-16.90M | $-16.71M | $-15.80M | $-14.61M | $-12.79M | $-10.91M | $-9.68M | $-7.60M | $-7.54M | $-6.94M | $-5.01M | $-2.05M |
| Net Income Ratio | - | - | - | - | -21122.50% | - | - | - | - | - | - | - | - | - | - | - |
| EPS | $-0.25 | $-0.43 | $-0.48 | $-0.56 | $-0.57 | $-0.65 | $-0.81 | $-0.75 | $-0.66 | $-0.56 | $-0.50 | $-0.40 | $-0.42 | $-0.49 | $-0.36 | $-0.15 |
| EPS Diluted | $-0.25 | $-0.43 | $-0.48 | $-0.56 | $-0.57 | $-0.65 | $-0.81 | $-0.75 | $-0.66 | $-0.56 | $-0.50 | $-0.40 | $-0.42 | $-0.49 | $-0.36 | $-0.15 |
| Weighted Average Shares Outstanding | 29.88M | 29.84M | 29.82M | 29.76M | 29.74M | 25.65M | 19.50M | 19.39M | 19.40M | 19.35M | 19.26M | 19.00M | 18.14M | 14.05M | 14.05M | 14.05M |
| Weighted Average Shares Outstanding Diluted | 29.88M | 29.84M | 29.82M | 29.76M | 29.74M | 25.65M | 19.50M | 19.39M | 19.40M | 19.35M | 19.26M | 19.00M | 18.14M | 14.05M | 14.05M | 14.05M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $21.35M | $15.65M | $27.22M | $12.10M | $4.07M |
| Short Term Investments | $62.27M | $91.65M | $68.84M | $46.46M | $- |
| Cash and Short Term Investments | $83.62M | $107.30M | $96.06M | $58.55M | $4.07M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $2.64M | $3.21M | $2.56M | $1.55M | $164.00K |
| Total Current Assets | $86.26M | $110.51M | $98.62M | $60.11M | $4.23M |
| Property Plant Equipment Net | $- | $- | $53.00K | $- | $- |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $5.02M | $27.19M | $3.22M | $3.49M | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $804.00K | $1.04M | $667.00K | $1.72M | $- |
| Total Non-Current Assets | $5.83M | $28.24M | $3.94M | $5.21M | $- |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $92.09M | $138.74M | $102.56M | $65.32M | $4.23M |
| Account Payables | $3.32M | $2.68M | $2.12M | $1.06M | $132.00K |
| Short Term Debt | $- | $- | $106.00K | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $6.92M | $11.37M | $4.96M | $2.33M | $1.33M |
| Total Current Liabilities | $10.24M | $14.04M | $7.19M | $3.40M | $1.46M |
| Long Term Debt | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $2.00K | $109.33M | $23.09M |
| Total Non-Current Liabilities | $- | $- | $2.00K | $109.33M | $23.09M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $10.24M | $14.04M | $7.19M | $112.73M | $24.55M |
| Preferred Stock | $- | $- | $102.56M | $109.32M | $23.07M |
| Common Stock | $- | $- | $- | $- | $- |
| Retained Earnings | $-205.78M | $-154.46M | $-89.72M | $-47.38M | $-20.32M |
| Accumulated Other Comprehensive Income Loss | $31.00K | $275.00K | $-374.00K | $-27.00K | $- |
| Other Total Stockholders Equity | $287.59M | $278.88M | $185.47M | $- | $-23.07M |
| Total Stockholders Equity | $81.85M | $124.70M | $95.37M | $-47.41M | $-20.32M |
| Total Equity | $81.85M | $124.70M | $95.37M | $-47.41M | $-20.32M |
| Total Liabilities and Stockholders Equity | $92.09M | $138.74M | $102.56M | $65.32M | $4.23M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $92.09M | $138.74M | $102.56M | $65.32M | $4.23M |
| Total Investments | $67.29M | $118.84M | $72.06M | $49.94M | $- |
| Total Debt | $- | $- | $53.00K | $- | $- |
| Net Debt | $-21.35M | $-15.65M | $-27.17M | $-12.10M | $-4.07M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $21.35M | $33.50M | $26.77M | $24.69M | $15.65M | $32.62M | $40.81M | $26.71M | $27.22M | $28.80M | $40.62M | $82.52M | $12.10M | $-4.07M |
| Short Term Investments | $62.27M | $59.92M | $77.77M | $89.52M | $91.65M | $91.20M | $54.45M | $61.81M | $68.84M | $75.58M | $72.77M | $35.84M | $46.46M | $8.14M |
| Cash and Short Term Investments | $83.62M | $93.43M | $104.54M | $114.21M | $107.30M | $123.82M | $95.26M | $88.52M | $96.06M | $104.38M | $113.39M | $118.35M | $58.55M | $4.07M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $2.64M | $4.26M | $2.90M | $2.10M | $3.21M | $2.59M | $2.95M | $1.80M | $2.56M | $5.75M | $6.96M | $2.83M | $1.55M | $- |
| Total Current Assets | $86.26M | $97.69M | $107.44M | $116.31M | $110.51M | $126.41M | $98.21M | $90.32M | $98.62M | $107.30M | $116.88M | $119.78M | $60.11M | $4.07M |
| Property Plant Equipment Net | $- | $- | $- | $- | $- | $- | $13.00K | $34.00K | $53.00K | $73.00K | $13.00K | $32.00K | $- | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $5.02M | $- | $- | $3.90M | $27.19M | $26.36M | $- | $- | $3.22M | $1.99M | $2.42M | $- | $3.49M | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $804.00K | $- | $1.04M | $1.04M | $1.04M | $1.04M | $707.00K | $734.00K | $667.00K | $647.00K | $707.00K | $688.00K | $1.72M | $-4.07M |
| Total Non-Current Assets | $5.83M | $- | $1.04M | $4.95M | $28.24M | $27.40M | $720.00K | $768.00K | $3.94M | $2.71M | $3.14M | $720.00K | $5.21M | $-4.07M |
| Other Assets | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $0 | $-0 | $- | $- | $- |
| Total Assets | $92.09M | $97.69M | $108.48M | $121.26M | $138.74M | $153.81M | $98.93M | $91.08M | $102.56M | $110.01M | $120.02M | $120.50M | $65.32M | $- |
| Account Payables | $3.32M | $1.71M | $1.89M | $2.43M | $2.68M | $4.88M | $3.13M | $3.54M | $2.12M | $1.44M | $1.61M | $2.61M | $1.06M | $- |
| Short Term Debt | $- | $- | $- | $- | $- | $- | $26.00K | $68.00K | $53.00K | $146.00K | $26.00K | $64.00K | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $8.01M | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $6.92M | $8.31M | $8.24M | $8.23M | $11.37M | $9.96M | $8.00M | $4.95M | $5.01M | $2.85M | $2.51M | $2.41M | $2.33M | $- |
| Total Current Liabilities | $10.24M | $10.02M | $10.13M | $10.66M | $14.04M | $14.84M | $11.16M | $8.57M | $7.19M | $4.43M | $4.15M | $5.09M | $3.40M | $- |
| Long Term Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $1.00K | $1.00K | $2.00K | $3.00K | $4.00K | $6.00K | $109.33M | $- |
| Total Non-Current Liabilities | $- | $- | $- | $8.23M | $- | $- | $1.00K | $1.00K | $2.00K | $3.00K | $4.00K | $6.00K | $109.33M | $- |
| Other Liabilities | $- | $- | $- | $-8.23M | $- | $- | $-0 | $- | $- | $0 | $- | $- | $- | $- |
| Total Liabilities | $10.24M | $10.02M | $10.13M | $10.66M | $14.04M | $14.84M | $11.16M | $8.57M | $7.19M | $4.43M | $4.15M | $5.09M | $112.73M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $110.01M | $120.02M | $120.50M | $109.32M | $23.07M |
| Common Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Retained Earnings | $-205.78M | $-198.25M | $-185.51M | $-171.07M | $-154.46M | $-137.56M | $-120.85M | $-105.05M | $-89.72M | $-77.88M | $-66.54M | $-56.42M | $-47.38M | $- |
| Accumulated Other Comprehensive Income Loss | $31.00K | $- | $-27.00K | $53.00K | $275.00K | $-122.00K | $-119.00K | $-175.00K | $-374.00K | $-541.00K | $-360.00K | $-158.00K | $-27.00K | $-20.32M |
| Other Total Stockholders Equity | $287.59M | $285.93M | $283.89M | $281.62M | $278.88M | $276.65M | $208.73M | $187.74M | $185.47M | $184.00M | $182.76M | $171.99M | $-109.32M | $- |
| Total Stockholders Equity | $81.85M | $87.67M | $98.35M | $110.60M | $124.70M | $138.97M | $87.76M | $82.52M | $95.37M | $105.57M | $115.86M | $115.41M | $-47.41M | $2.75M |
| Total Equity | $81.85M | $87.67M | $98.35M | $110.60M | $124.70M | $138.97M | $87.76M | $82.52M | $95.37M | $105.57M | $115.86M | $115.41M | $-47.41M | $2.75M |
| Total Liabilities and Stockholders Equity | $92.09M | $97.69M | $108.48M | $121.26M | $138.74M | $153.81M | $98.93M | $91.08M | $102.56M | $110.01M | $120.02M | $120.50M | $65.32M | $2.75M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $92.09M | $97.69M | $108.48M | $121.26M | $138.74M | $153.81M | $98.93M | $91.08M | $102.56M | $110.01M | $120.02M | $120.50M | $65.32M | $2.75M |
| Total Investments | $67.29M | $59.92M | $77.77M | $93.42M | $118.84M | $117.56M | $54.45M | $61.81M | $72.06M | $77.57M | $75.19M | $35.84M | $49.94M | $8.14M |
| Total Debt | $- | $- | $- | $- | $- | $- | $13.00K | $34.00K | $53.00K | $73.00K | $13.00K | $32.00K | $- | $- |
| Net Debt | $-21.35M | $-33.50M | $-26.77M | $-24.69M | $-15.65M | $-32.62M | $-40.80M | $-26.68M | $-27.17M | $-28.73M | $-40.60M | $-82.49M | $-12.10M | $4.07M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-51.32M | $-64.73M | $-40.96M | $-21.54M | $-13.60M |
| Depreciation and Amortization | $- | $- | $-692.00K | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $8.34M | $8.41M | $4.39M | $974.00K | $40.00K |
| Change in Working Capital | $-3.00M | $5.83M | $3.72M | $32.00K | $1.22M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $641.00K | $553.00K | $2.50M | $417.00K | $81.00K |
| Other Working Capital | $-3.64M | $5.28M | $1.22M | $-385.00K | $1.14M |
| Other Non Cash Items | $-3.28M | $-2.80M | $77.00K | $53.00K | $6.97M |
| Net Cash Provided by Operating Activities | $-49.26M | $-53.29M | $-33.46M | $-20.48M | $-5.36M |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $-46.75M | $-132.18M | $-93.84M | $-77.27M | $- |
| Sales Maturities of Investments | $101.34M | $88.90M | $72.06M | $27.25M | $- |
| Other Investing Activities | $- | $- | $-21.77K | $-50.02K | $- |
| Net Cash Used for Investing Activities | $54.59M | $-43.28M | $-21.77M | $-50.02M | $- |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $84.53M | $70.37M | $78.53M | $3.84M |
| Common Stock Repurchased | $- | $- | $-11.00K | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $372.00K | $465.00K | $-11.00K | $78.53M | $3.84M |
| Net Cash Used Provided by Financing Activities | $372.00K | $84.99M | $70.36M | $78.53M | $3.84M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $5.70M | $-11.57M | $15.12M | $8.03M | $-1.53M |
| Cash at End of Period | $21.35M | $15.65M | $27.22M | $12.10M | $4.07M |
| Cash at Beginning of Period | $15.65M | $27.22M | $12.10M | $4.07M | $5.60M |
| Operating Cash Flow | $-49.26M | $-53.29M | $-33.46M | $-20.48M | $-5.36M |
| Capital Expenditure | $- | $- | $- | $- | $- |
| Free Cash Flow | $-49.26M | $-53.29M | $-33.46M | $-20.48M | $-5.36M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-7.52M | $-12.75M | $-14.44M | $-16.62M | $-16.90M | $-16.71M | $-15.80M | $-15.32M | $-11.84M | $-11.34M | $-10.12M | $-7.66M | $-7.54M | $-6.94M | $-5.01M | $-2.05M |
| Depreciation and Amortization | $- | $- | $- | $- | $414.00K | $- | $21.00K | $-435.00K | $-692.00K | $20.00K | $19.00K | $1.00K | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $21.00K | $- | $-21.00K | $- | $- | $-20.00K | $-19.00K | $-1.00K | $- | $- | $- | $- |
| Stock Based Compensation | $1.78M | $1.90M | $2.27M | $2.38M | $2.23M | $2.17M | $1.94M | $2.07M | $1.47M | $1.23M | $1.24M | $449.00K | $433.00K | $354.00K | $179.00K | $8.00K |
| Change in Working Capital | $1.04M | $-431.00K | $-1.33M | $-2.27M | $-1.10M | $3.38M | $1.48M | $2.08M | $3.09M | $849.00K | $-663.00K | $445.00K | $-1.90M | $1.88M | $-440.00K | $497.00K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $1.61M | $-174.00K | $-548.00K | $-243.00K | $-2.11M | $1.65M | $-414.00K | $1.42M | $681.00K | $-171.00K | $441.00K | $1.55M | $-946.00K | $711.00K | $273.00K | $379.00K |
| Other Working Capital | $-570.00K | $-257.00K | $-782.00K | $-2.03M | $1.01M | $1.73M | $1.89M | $652.00K | $2.41M | $1.02M | $-1.10M | $-1.10M | $-958.00K | $1.17M | $-713.00K | $118.00K |
| Other Non Cash Items | $-567.00K | $-731.00K | $-890.00K | $1.54M | $-1.31M | $-640.00K | $-440.00K | $19.00K | $337.00K | $-225.00K | $-54.00K | $19.00K | $23.00K | $19.00K | $11.00K | $379.00K |
| Net Cash Provided by Operating Activities | $-5.27M | $-12.01M | $-14.38M | $-17.59M | $-17.07M | $-11.80M | $-12.82M | $-11.60M | $-7.64M | $-9.49M | $-9.60M | $-6.74M | $-8.99M | $-4.69M | $-5.26M | $-1.54M |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-24.38M | $-9.78M | $-12.59M | $- | $-19.83M | $-85.21M | $-13.12M | $-14.01M | $-17.45M | $-22.41M | $-52.99M | $-998.00K | $-16.00M | $-11.99M | $-49.28M | $- |
| Sales Maturities of Investments | $17.50M | $28.50M | $29.05M | $26.29M | $20.25M | $22.75M | $21.00M | $24.90M | $23.50M | $20.09M | $13.50M | $14.97M | $22.25M | $5.00M | $- | $- |
| Other Investing Activities | $- | $- | $- | $26.29M | $420 | $-62.46K | $7.88K | $10.89K | $6.05K | $-2.32K | $-39.49K | $13.98M | $6.25M | $-6.99M | $-49.28M | $- |
| Net Cash Used for Investing Activities | $-6.88M | $18.72M | $16.46M | $26.29M | $420.00K | $-62.46M | $7.88M | $10.89M | $6.05M | $-2.32M | $-39.49M | $13.98M | $6.25M | $-6.99M | $-49.28M | $- |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $-202.00K | $- | $349.00K | $-321.00K | $65.80M | $19.05M | $199.00K | $70.38M | $-10.00K | $7.18M | $63.20M | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-11.00K | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.82M | $- | $- | $- | $- |
| Other Financing Activities | $- | $23.00K | $- | $349.00K | $- | $266.00K | $- | $199.00K | $1.81M | $- | $- | $1.81M | $-969.00K | $-240.00K | $- | $79.74M |
| Net Cash Used Provided by Financing Activities | $- | $23.00K | $- | $349.00K | $-321.00K | $66.07M | $19.05M | $199.00K | $70.36M | $-10.00K | $7.18M | $63.19M | $-969.00K | $-240.00K | $- | $79.74M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $-70.36M | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-12.15M | $6.74M | $2.08M | $9.05M | $-16.97M | $-8.20M | $14.10M | $-510.00K | $-1.58M | $-11.81M | $-41.90M | $70.42M | $-3.72M | $-11.92M | $-54.54M | $78.20M |
| Cash at End of Period | $21.35M | $33.50M | $26.77M | $24.69M | $15.65M | $32.62M | $40.81M | $26.71M | $27.22M | $28.80M | $40.62M | $82.52M | $12.10M | $15.81M | $27.73M | $82.27M |
| Cash at Beginning of Period | $33.50M | $26.77M | $24.69M | $15.65M | $32.62M | $40.81M | $26.71M | $27.22M | $28.80M | $40.62M | $82.52M | $12.10M | $15.81M | $27.73M | $82.27M | $4.07M |
| Operating Cash Flow | $-5.27M | $-12.01M | $-14.38M | $-17.59M | $-17.07M | $-11.80M | $-12.82M | $-11.60M | $-7.64M | $-9.49M | $-9.60M | $-6.74M | $-8.99M | $-4.69M | $-5.26M | $-1.54M |
| Capital Expenditure | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Free Cash Flow | $-5.27M | $-12.01M | $-14.38M | $-17.59M | $-17.07M | $-11.80M | $-12.82M | $-11.60M | $-7.64M | $-9.49M | $-9.60M | $-6.74M | $-8.99M | $-4.69M | $-5.26M | $-1.54M |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
$1.22
Stock Price
$36.72M
Market Cap
22
Employees
Menlo Park, CA
Location
Revenue (FY 2023)
$-
0.0% YoY
Net Income (FY 2023)
$-64.73M
0.0% YoY
EPS (FY 2023)
$-2.74
0.0% YoY
Free Cash Flow (FY 2023)
$-49.26M
7.6% YoY
Profitability
Gross Margin
0.0%
Net Margin
0.0%
ROE
%
ROA
%
Valuation
P/E Ratio
0.00
P/S Ratio
0.00
EV/EBITDA
0.00
Market Cap
$36.72M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-49.26M
7.6% YoY
Free Cash Flow
$-49.26M
7.6% YoY
Balance Sheet Summary
Total Assets
$92.09M
-33.6% YoY
Total Debt
$-
0.0% YoY
Shareholder Equity
$81.85M
-100.0% YoY
Dividend Overview
$0.66
Latest Dividend
%
Dividend Yield
%
Payout Ratio
Recent Dividend History
| Date | Amount | Type |
|---|---|---|
| 2018-01-11 | $0.66 | January 11, 18 |
| 2017-10-12 | $0.66 | October 12, 17 |
| 2017-07-12 | $0.66 | July 12, 17 |
| 2017-04-11 | $0.66 | April 11, 17 |
| 2017-01-11 | $0.66 | January 11, 17 |
| 2016-10-12 | $0.66 | October 12, 16 |
| 2016-07-13 | $0.66 | July 13, 16 |
| 2016-04-13 | $0.66 | April 13, 16 |
| 2016-01-13 | $0.66 | January 13, 16 |
| 2015-10-13 | $0.66 | October 13, 15 |
AN2 Therapeutics Dividends
Explore AN2 Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
0.00x
AN2 Therapeutics Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.65625 | $0.65625 | January 11, 2018 | |||
| $0.65625 | $0.65625 | October 12, 2017 | |||
| $0.65625 | $0.65625 | July 12, 2017 | |||
| $0.65625 | $0.65625 | April 11, 2017 | |||
| $0.65625 | $0.65625 | January 11, 2017 | |||
| $0.65625 | $0.65625 | October 12, 2016 | |||
| $0.65625 | $0.65625 | July 13, 2016 | |||
| $0.65625 | $0.65625 | April 13, 2016 | |||
| $0.65625 | $0.65625 | January 13, 2016 | |||
| $0.65625 | $0.65625 | October 13, 2015 | |||
| $0.57604 | $0.57604 | July 13, 2015 |
AN2 Therapeutics News
Read the latest news about AN2 Therapeutics, including recent articles, headlines, and updates.
AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the fourth quarter and year ended December 31, 2024. "Epetraborole demonstrated potential proof-of-concept in Phase 2, achieving nominal statistical significance on two patient-reported outcome measures in patients with treatment-refractory MA.
AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Leerink Partners Global Healthcare Conference. Details of the event are as follows: Leerink Partners Global Healthcare Conference Eric Easom, Co-Founder, Chairman, President and CEO, wil.
AN2 Therapeutics to Participate at Upcoming Investor Conferences
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in March. Details of the events are as follows: TD Cowen 45th Annual Health Care Conference Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Monda.
AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Details of the event are as follows: Oppenheimer 35th Annual Healthcare Life Sciences Conference (virtual) Eric Easom, Co-Fou.
AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the quarter ended September 30, 2024 and provided an update from its ongoing analysis of data from the Phase 2 portion of the EBO-301 trial. “Treatment options for patients with refractory MAC lung disease are extremely limited. Many of these.
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company has received a second year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel, boron containing small molecules for the treatment of tuberculosis (TB) and malaria. “We are appreciative of the Gates Foun.
Why Is AN2 Therapeutics (ANTX) Stock Down 35% Today?
AN2 Therapeutics (NASDAQ: ANTX ) stock is taking a beating on Friday after the company provided an update on its EBO-301 Phase 2/3 study. AN2 Therapeutics notes that information comes from the Phase 2 study of epetraborole as an optimized background regimen (OBR) in treatment-refractory MAC lung disease.
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform today announced topline results from the Phase 2 part of the EBO-301 Phase 2/3 study evaluating epetraborole on top of an optimized background regimen (OBR) in treatment-refractory MAC lung disease. The Phase 2 part of the study met its primary objective of demonstrating the poten.
Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround
AN2 Therapeutics (ANTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2024. “The Phase 2 topline data, expected to be available in August, will include the first clinical efficacy data for epetraborole in patients with treatment-refractory MAC. The patients enrolled in EBO-301.
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023. “AN2's cash position remains strong as we advance our innovative boron-based pipeline. Following the recent meeting of the independent Data Safety Monitoring Board, we continue to bel.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Levi & Korsinsky, LLP Investigates Possible Securities Fraud Violations by AN2 Therapeutics, Inc. (ANTX)
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AN2 Therapeutics, Inc. ("AN2 Therapeutics") (NASDAQ:ANTX) concerning possible violations of federal securities laws. Before the market open on February 12, 2024, AN2 Therapeutics announced a pause in Phase 3 enrollment in its seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review.
ANTX ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by AN2 Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AN2 Therapeutics, Inc. ("AN2 Therapeutics") (NASDAQ:ANTX) concerning possible violations of federal securities laws. Before the market open on February 12, 2024, AN2 Therapeutics announced a pause in Phase 3 enrollment in its seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review.
AN2 Therapeutics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - ANTX
NEW YORK, NY / ACCESSWIRE / February 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AN2 Therapeutics, Inc. ("AN2 Therapeutics") (NASDAQ:ANTX) concerning possible violations of federal securities laws. Before the market open on February 12, 2024, AN2 Therapeutics announced a pause in Phase 3 enrollment in its seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review.
AN2 Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ANTX
NEW YORK, NY / ACCESSWIRE / February 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AN2 Therapeutics, Inc. ("AN2 Therapeutics") (NASDAQ:ANTX) concerning possible violations of federal securities laws. Before the market open on February 12, 2024, AN2 Therapeutics announced a pause in Phase 3 enrollment in its seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review.
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AN2 Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or "the Company") (NASDAQ:ANTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the company's decision to voluntarily pause Phase 3 enrollment in the seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review. The double-blind, placebo-controlled trial has t.
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. Details of the event is as follows: Oppenheimer 34th Annual Healthcare Life Sciences Conference (virtual) Eric Easom, Co-Founder,.
Recent Price Trend in AN2 Therapeutics, Inc. (ANTX) is Your Friend, Here's Why
AN2 Therapeutics, Inc. (ANTX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
AN2 Therapeutics to Present at Upcoming Investor Conferences
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in November. Stifel 2023 Healthcare Conference Eric Easom, Co-Founder, President and CEO will provide a corporate overview on Wednesday, November 15 at 3:00 p.m. ET. 6th Annual Ev.
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that it has received an exclusive license from the University of Georgia Research Foundation to advance the development of a boron-containing small molecule for Chagas disease. These boron-based molecules were originally discovered by researchers at Anacor.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ANTX.